title: Tysabri's return draws cautious optimism. Pharmacies, infusion centers must register to participate.
authors.forename: Kate
authors.initials: K
authors.lastname: Traynor
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D017277:Drug Approval; D004348:Drug Labeling; D007722:Health Knowledge, Attitudes, Practice; D018718:Home Infusion Therapy; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D010342:Patient Acceptance of Health Care; D018579:Patient Selection; D010594:Pharmacies / Q000592:standards; D017410:Practice Guidelines as Topic; D012042:Registries; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab